BioNexus Gene Lab Gross Profit 2019-2025 | BGLC
BioNexus Gene Lab gross profit from 2019 to 2025. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
|
BioNexus Gene Lab Annual Gross Profit (Millions of US $) |
|
|---|---|
| 2024 | $1 |
| 2023 | $1 |
| 2022 | $1 |
| 2021 | $2 |
| 2020 | $2 |
| 2019 | $0 |
| 2018 | $0 |
|
BioNexus Gene Lab Quarterly Gross Profit (Millions of US $) |
|
|---|---|
| 2025-09-30 | $0 |
| 2025-06-30 | $0 |
| 2025-03-31 | $0 |
| 2024-12-31 | $0 |
| 2024-09-30 | $0 |
| 2024-06-30 | $0 |
| 2024-03-31 | $0 |
| 2023-12-31 | $0 |
| 2023-09-30 | $0 |
| 2023-06-30 | $0 |
| 2023-03-31 | $0 |
| 2022-12-31 | $0 |
| 2022-09-30 | $0 |
| 2022-06-30 | $0 |
| 2022-03-31 | $0 |
| 2021-12-31 | $1 |
| 2021-09-30 | $1 |
| 2021-06-30 | $0 |
| 2021-03-31 | $1 |
| 2020-12-31 | $0 |
| 2020-09-30 | $1 |
| 2020-06-30 | $0 |
| 2020-03-31 | $1 |
| 2019-12-31 | $0 |
| 2019-09-30 | $0 |
| 2019-06-30 | $0 |
| 2019-03-31 | $0 |
| 2018-12-31 | $0 |
| 2018-09-30 | $0 |
| 2018-06-30 | $0 |
| 2018-03-31 | $0 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $0.005B | $0.010B |
| BioNexus Gene Lab Corp. is an emerging company in the business of selling chemical raw materials principally in the Southeast Asia region and the development of biopsy tests for early diagnosis and personalized health management. BioNexus Gene Lab Corp. is based in KUALA LUMPUR, Malaysia. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $153.002B | 27.77 |
| HCA Healthcare (HCA) | United States | $114.483B | 17.75 |
| CVS Health (CVS) | United States | $99.460B | 11.44 |
| Elevance Health (ELV) | United States | $75.335B | 11.24 |
| Cencora (COR) | United States | $69.692B | 21.99 |
| Natera (NTRA) | United States | $28.085B | 0.00 |
| DiDi Global (DIDIY) | China | $23.132B | 21.37 |
| Labcorp Holdings (LH) | United States | $22.980B | 17.52 |
| Viatris (VTRS) | United States | $16.793B | 6.26 |
| Medpace Holdings (MEDP) | United States | $15.268B | 37.90 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $15.244B | 0.00 |
| Solventum (SOLV) | United States | $13.550B | 13.15 |
| BioMerieux (BMXMF) | France | $13.324B | 0.00 |
| ICON (ICLR) | Ireland | $12.161B | 12.07 |
| CochLear (CHEOY) | Australia | $11.774B | 0.00 |
| Revvity (RVTY) | United States | $11.518B | 20.04 |
| Charles River Laboratories (CRL) | United States | $9.312B | 17.93 |
| Sonic Healthcare (SKHHY) | Australia | $7.878B | 0.00 |
| Avantor (AVTR) | United States | $7.677B | 11.73 |
| BrightSpring Health Services (BTSG) | United States | $7.156B | 42.67 |
| HealthEquity (HQY) | United States | $6.788B | 25.38 |
| Caris Life Sciences,�Inc (CAI) | United States | $6.207B | 0.00 |
| PACS (PACS) | United States | $6.058B | 36.84 |
| Bausch + Lomb (BLCO) | Canada | $6.022B | 39.53 |
| Sotera Health (SHC) | United States | $5.043B | 24.32 |
| Alignment Healthcare (ALHC) | United States | $4.352B | 0.00 |
| Amplifon S.p.A (AMFPF) | Italy | $3.532B | 20.61 |
| Concentras Parent (CON) | United States | $3.012B | 18.80 |
| GeneDx Holdings (WGS) | United States | $2.436B | 42.79 |
| Organon (OGN) | United States | $2.134B | 2.25 |
| Establishment Labs Holdings (ESTA) | United States | $1.999B | 0.00 |
| Progyny (PGNY) | United States | $1.892B | 37.20 |
| Pediatrix Medical (MD) | United States | $1.794B | 10.71 |
| Surgery Partners (SGRY) | United States | $1.754B | 22.60 |
| Ardent Health (ARDT) | United States | $1.280B | 4.18 |
| InnovAge Holding (INNV) | United States | $1.134B | 167.20 |
| CareDx (CDNA) | United States | $1.001B | 16.36 |
| Teladoc Health (TDOC) | United States | $0.889B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $0.828B | 13.56 |
| Nutex Health (NUTX) | United States | $0.706B | 5.40 |
| Omada Health (OMDA) | United States | $0.675B | 0.00 |
| Embecta (EMBC) | United States | $0.643B | 3.59 |
| Sonida Senior Living (SNDA) | United States | $0.642B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.594B | 0.00 |
| Enhabit (EHAB) | United States | $0.563B | 25.30 |
| Charming Medical (MCTA) | Hong Kong, SAR China | $0.497B | 0.00 |
| SBC Medicals (SBC) | United States | $0.466B | 8.57 |
| CryoPort (CYRX) | United States | $0.437B | 0.00 |
| Strata Critical Medical (SRTA) | United States | $0.409B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.391B | 82.38 |
| Auna S.A (AUNA) | Luxembourg | $0.352B | 5.67 |
| So-Young (SY) | China | $0.339B | 0.00 |
| Agilon Health (AGL) | United States | $0.269B | 0.00 |
| Shoulder Innovations (SI) | United States | $0.262B | 0.00 |
| Oncology Institute (TOI) | United States | $0.257B | 0.00 |
| Beauty Health (SKIN) | United States | $0.163B | 0.00 |
| LifeMD (LFMD) | United States | $0.151B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.134B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.097B | 0.00 |
| Biodesix (BDSX) | United States | $0.083B | 0.00 |
| DocGo (DCGO) | United States | $0.076B | 0.00 |
| Park Dental Partners (PARK) | United States | $0.070B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.041B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.039B | 0.00 |
| Pomdoctor - (POM) | China | $0.023B | 0.00 |
| Synergy CHC (SNYR) | United States | $0.020B | 6.10 |
| OSR Holdings (OSRH) | United States | $0.014B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.012B | 0.00 |
| Lifeward (LFWD) | United States | $0.010B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.009B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.008B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.006B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| INVO Fertility (IVF) | United States | $0.003B | 0.00 |
| XWELL (XWEL) | United States | $0.002B | 0.00 |
| Aclarion (ACON) | United States | $0.002B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |